NSE: GLAXO | BSE: 500660

Expensive Performer

Download real time

2880.35 43.45 (1.53%)

56.37% Gain from 52W Low

111.7K NSE+BSE Volume

NSE 28 Mar, 2025 3:31 PM (IST)

48,794.9

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

Search Inside the pdf :

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024

2880.35

1.53%

Superior execution and lower RM costs drive earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Glaxo Pharma (GLXO) delivered better-than-expected 1QFY25 performance. The robust growth in key brands, young potential brands.

GlaxoSmithKline Phar.. has an average target of 2630.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2024

2880.35

1.53%

On road to recovery

Hold: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSK) Q1FY25 result was ahead of our expectations driven by mixed improvement and curb in overhead cost.

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

27 Jul 2023

2880.35

1.53%

Launch cost dents margins

Hold: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q1FY24 performance was largely in line with expectations, though EBITDA margin was weaker due to marketing cost of the newly launched Shingrix (herpes zoster vaccine). GSKP’s focus on volume growth forms the crux of its market-approach strategy as pricing pressure forces companies to think differently.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 47.97% in the last 1 Year

GlaxoSmithKline Pharmaceuticals Ltd.

19 May 2023

2880.35

1.53%

Mandated price cuts dampen margins

Hold: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q4FY23 performance was disappointing with margins taking a hit due to unfavourable mix and price cuts on the NLEM portfolio (42% of sales). GSK’s focus on volume growth forms the crux of its market-approach strategy as pricing pressures force it to think differently.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 26.64% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

17 May 2023

2880.35

1.53%

Downward revision in realization adversely impacts earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Phar.. has an average target of 2630.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

16 Mar 2023

2880.35

1.53%

Outlook - A Mixed Bag

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Number of FII/FPI investors increased from 337 to 347 in Dec 2024 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

08 Feb 2023

2880.35

1.53%

Prudent cost controls support margins

Buy: GlaxoSmithKline Pharmaceut...

Recommendation Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q3FY23 performance beat our estimates on the profitability front, led by prudent cost controls. Revenues declined 1.7% YoY to Rs8bn (I-Sec: Rs8.8bn) with slowdown in vaccine sales. EBITDA margins saw strong YoY expansion of 430bps (+50bps QoQ) to 28.5%, largely supported by gross margin expansion and lower ‘other expenses’.

Number of FII/FPI investors increased from 337 to 347 in Dec 2024 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

14 Nov 2022

2880.35

1.53%

Controlled costs support margins

Accumulate: GlaxoSmithKline Pharmaceut...

Target

ICICI Securities Limited

GlaxoSmithKline Pharmaceuticals’ (GSKP) Q2FY23 performance beat our estimates on the profitability front, led by prudent cost controls. Revenue (excluding divested brands) declined 1.8% YoY to Rs9.2bn (I-Sec: Rs9.6bn).

GlaxoSmithKline Pharmaceuticals Ltd. has gained 26.64% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

12 Nov 2022

2880.35

1.53%

General medicines/specialty - the key drivers for sales growth

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Phar.. has an average target of 2630.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

24 Aug 2022

2880.35

1.53%

Analyst call highlights

Hold: GlaxoSmithKline Pharmaceut...

ICICI Securities Limited

Company believes its key brands and therapies would continue to grow. It has been able to maintain its market share in key brands and expects to improve on it gradually.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 26.64% in the last 3 Months

No results found

Is GlaxoSmithKline Pharmaceuticals Ltd. worth buying?

118 Votes:

Buy 65.25%

Sell 22.03%

Hold 12.71%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf